U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H16ClF2N3O4S
Molecular Weight 467.874
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GS-9224

SMILES

CN(C1=C2CN(CC3=CC(Cl)=C(F)C=C3F)C(=O)C2=C(O)C4=NC=CC=C14)S(C)(=O)=O

InChI

InChIKey=NOOXOJVRDAFYDD-UHFFFAOYSA-N
InChI=1S/C20H16ClF2N3O4S/c1-25(31(2,29)30)18-11-4-3-5-24-17(11)19(27)16-12(18)9-26(20(16)28)8-10-6-13(21)15(23)7-14(10)22/h3-7,27H,8-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H16ClF2N3O4S
Molecular Weight 467.874
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 12:05:30 GMT 2023
Edited
by admin
on Sat Dec 16 12:05:30 GMT 2023
Record UNII
95NFK5HO9J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GS-9224
Common Name English
METHANESULFONAMIDE, N-(7-((5-CHLORO-2,4-DIFLUOROPHENYL)METHYL)-7,8-DIHYDRO-9-HYDROXY-8-OXO-6H-PYRROLO(3,4-G)QUINOLIN-5-YL)-N-METHYL-
Systematic Name English
N-(7-((5-CHLORO-2,4-DIFLUORO-PHENYL)METHYL)-9-HYDROXY-8-OXO-6H-PYRROLO(3,4-G)QUINOLIN-5-YL)-N-METHYL-METHANESULFONAMIDE
Systematic Name English
Code System Code Type Description
FDA UNII
95NFK5HO9J
Created by admin on Sat Dec 16 12:05:30 GMT 2023 , Edited by admin on Sat Dec 16 12:05:30 GMT 2023
PRIMARY
PUBCHEM
16097720
Created by admin on Sat Dec 16 12:05:30 GMT 2023 , Edited by admin on Sat Dec 16 12:05:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID801102770
Created by admin on Sat Dec 16 12:05:30 GMT 2023 , Edited by admin on Sat Dec 16 12:05:30 GMT 2023
PRIMARY
CAS
915409-66-4
Created by admin on Sat Dec 16 12:05:30 GMT 2023 , Edited by admin on Sat Dec 16 12:05:30 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
GS-9224, a backup compound to GS-9160, entered clinical trials in the fourth financial quarter of 2006. Following the results of a Phase I clinical study, however, Gilead Sciences announced the discontinuation of GS-9224 development due to an unexpected short half-life. To our knowledge, the structural details of GS-9224 have not yet been disclosed to the public.